Skip to main content
Journal cover image

Safety of histamine-2 receptor blockers in hospitalized VLBW infants.

Publication ,  Journal Article
Romaine, A; Ye, D; Ao, Z; Fang, F; Johnson, O; Blake, T; Benjamin, DK; Cotten, CM; Testoni, D; Clark, RH; Chu, VH; Smith, PB; Hornik, CP ...
Published in: Early Hum Dev
August 2016

BACKGROUND: Histamine-2 receptor (H2) blockers are often used in very low birth weight infants despite lack of population specific efficacy and safety data. AIMS: We sought to describe safety and temporal trends in histamine-2 receptor (H2) blocker use in hospitalized very low birth weight (VLBW) infants. STUDY DESIGN: We conducted a retrospective cohort study using a clinical database populated by an electronic health record shared by 348 neonatal intensive care units in the United States. SUBJECTS: We included all VLBW infants without major congenital anomalies. OUTCOME MEASURES: We used multivariable logistic regression with generalizing estimating equations to evaluate the association between days of H2 blocker exposure and risk of: 1) death or necrotizing enterocolitis (NEC); 2) death or sepsis; and 3) death, NEC, or sepsis. RESULTS: Of 127,707 infants, 20,288 (16%) were exposed to H2 blockers for a total of 6,422,352days. Median gestational age for infants exposed to H2 blockers was 27weeks (25th 75th percentile 26, 29). H2 blocker use decreased from 18% of infants in 1997 to 8% in 2012 (p<0.001). On multivariable analysis, infants were at increased risk of the combined outcome of death, NEC, or sepsis on days exposed to H2 blockers (odds ratio=1.14) (95% confidence interval 1.08, 1.19). CONCLUSIONS: H2 blocker use is associated with increased risk of the combined outcome of death, NEC, or sepsis in hospitalized VLBW infants.

Duke Scholars

Published In

Early Hum Dev

DOI

EISSN

1872-6232

Publication Date

August 2016

Volume

99

Start / End Page

27 / 30

Location

Ireland

Related Subject Headings

  • Sepsis
  • Retrospective Studies
  • Pediatrics
  • Male
  • Intensive Care Units, Neonatal
  • Infant, Very Low Birth Weight
  • Infant, Newborn
  • Infant Mortality
  • Infant
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Romaine, A., Ye, D., Ao, Z., Fang, F., Johnson, O., Blake, T., … Best Pharmaceuticals for Children Act – Pediatric Trials Network, . (2016). Safety of histamine-2 receptor blockers in hospitalized VLBW infants. Early Hum Dev, 99, 27–30. https://doi.org/10.1016/j.earlhumdev.2016.05.010
Romaine, Andrew, Daniel Ye, Zachary Ao, Francia Fang, Octavious Johnson, Taylor Blake, Daniel K. Benjamin, et al. “Safety of histamine-2 receptor blockers in hospitalized VLBW infants.Early Hum Dev 99 (August 2016): 27–30. https://doi.org/10.1016/j.earlhumdev.2016.05.010.
Romaine A, Ye D, Ao Z, Fang F, Johnson O, Blake T, et al. Safety of histamine-2 receptor blockers in hospitalized VLBW infants. Early Hum Dev. 2016 Aug;99:27–30.
Romaine, Andrew, et al. “Safety of histamine-2 receptor blockers in hospitalized VLBW infants.Early Hum Dev, vol. 99, Aug. 2016, pp. 27–30. Pubmed, doi:10.1016/j.earlhumdev.2016.05.010.
Romaine A, Ye D, Ao Z, Fang F, Johnson O, Blake T, Benjamin DK, Cotten CM, Testoni D, Clark RH, Chu VH, Smith PB, Hornik CP, Best Pharmaceuticals for Children Act – Pediatric Trials Network. Safety of histamine-2 receptor blockers in hospitalized VLBW infants. Early Hum Dev. 2016 Aug;99:27–30.
Journal cover image

Published In

Early Hum Dev

DOI

EISSN

1872-6232

Publication Date

August 2016

Volume

99

Start / End Page

27 / 30

Location

Ireland

Related Subject Headings

  • Sepsis
  • Retrospective Studies
  • Pediatrics
  • Male
  • Intensive Care Units, Neonatal
  • Infant, Very Low Birth Weight
  • Infant, Newborn
  • Infant Mortality
  • Infant
  • Humans